Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery wins Best Contract Research Organisation Award at OBN Awards 2017

Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise, has been named as the winner of the Best Contract Research Organisation award at the OBN Awards 2017.

The OBN Awards 2017, now in their 9th year, celebrate innovation and outstanding achievement across the UK Life Sciences industry.  Categories are broad-ranging and include Biotech, Medtech, Synthetic Biology, Digital Healthcare and Investment.  This year OBN launched a brand-new category, Best Contract Research Organisation award, which looks to recognise the critical support services provided by CROs across the pharmaceutical, biotech and medtech industries.

The awards ceremony took place on 5th October 2017 in Oxford Town Hall, an elegant and prestigious setting in central Oxford.  The evening began with a networking drinks reception, followed by dinner and the awards presentation.  There was plenty of time afterwards for celebrating and catching-up with friends and colleagues from across the pharmaceutical industry.

The Best Contract Research Organisation award was received by Sygnature Discovery’s Dr Paul Clewlow, Senior VP, Business Development, and Dr Steve Young, VP, Business Development.  The Award was sponsored by Ipsen Bioinnovation.

Latest News

View All

New platform set to accelerate early-stage targeted…

Sygnature Discovery completes acquisition of SB Drug…

Sygnature Discovery partners the Oncology Development Programme…

Sygnature Discovery deploys Iktos’ AI technology ‘Makya™’